Aimen Farouk Shaaban

Aimen Farouk Shaaban

Auto-generated profile, based on publicly available information

Aimen Farouk Shaaban

Chicago Institute for Fetal Health, Ann & Robert H. Lurie Children's Hospital Chicago Illinois USA

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2000 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
KLKenneth W. Liechty
Kenneth W. Liechty
TMTippi C. MacKenzie
Tippi C. MacKenzie
ASAimen F. Shaaban
Aimen F. Shaaban
ARAntoneta Radu
Antoneta Radu
AMAnneMarie B. Moseley
AnneMarie B. Moseley
AFAlan W. Flake
Alan W. Flake

6 November 2013 in Nature
Verified
Journal Article
Closed access
PDF file
SEShokrollah Elahi
Shokrollah Elahi
JEJames M. Ertelt
James M. Ertelt
JKJeremy M. Kinder
Jeremy M. Kinder
TJTony T. Jiang
Tony T. Jiang
XZXuzhe Zhang
Xuzhe Zhang
SWSing Sing Way
Sing Sing Way

1 April 2008 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
EDEmily T. Durkin
Emily T. Durkin
DLDennis P. Lund
Dennis P. Lund
ASAimen F. Shaaban
Aimen F. Shaaban
MSMichael J. Schurr
Michael J. Schurr
SWSharon M. Weber
Sharon M. Weber
Intestinal malrotation in adulthood may present with a variety of chronic symptoms. Surgical intervention frequently leads to other complications in these patients. We hypothesized that the chronic nature of malrotation in adults could cause a delay in diagnosis and increased perioperative complications. All patients diagnosed with intestinal malrotation from July 2002 through July 2006 were included. IRB approval was obtained. Outcomes in patients less than 16 years of age were compared with outcomes from those older than 16. Presenting symptoms, initial diagnosis, results of imaging data, and time to diagnosis were evaluated. Surgical management, resulting complications, and rate of reoperation were analyzed. Twenty-four patients with intestinal malrotation were identified (age range, 10 days to 89 years old; 10 adults, 14 children). Seventy percent of adults experienced chronic symptoms for 6 months or more before the diagnosis of malrotation was made (children, 14%, p = 0.017). No patients in the adult group were initially diagnosed with malrotation, although 57% of children were correctly diagnosed at the time of presentation of symptoms (p=0.006). Postoperative complications occurred in 60% of adults, but in only 29% of children, though this did not reach significance (p=0.211). Forty percent of adult patients required reoperation (p=0.020). Intestinal malrotation in adults is often associated with a delay in diagnosis and increased morbidity. Enhanced awareness of this entity in adults may enhance patient counseling and improve therapeutic outcomes in these patients.

1 July 2015 in Cell
Verified
Journal Article
Closed access
JKJeremy M. Kinder
Jeremy M. Kinder
TJTony T. Jiang
Tony T. Jiang
JEJames M. Ertelt
James M. Ertelt
LXLijun Xin
Lijun Xin
BSBeverly S. Strong
Beverly S. Strong
SWSing Sing Way
Sing Sing Way

1 August 2002 in Blood
Verified
Journal Article
Closed access
PDF file
SHSatoshi Hayashi
Satoshi Hayashi
WPWilliam H. Peranteau
William H. Peranteau
ASAimen F. Shaaban
Aimen F. Shaaban
AFAlan W. Flake
Alan W. Flake
In utero hematopoietic stem cell transplantation (IUHSCTx) can achieve mixed hematopoietic chimerism and donor-specific tolerance without cytoreductive conditioning or immunosuppression. The primary limitation to the clinical application of IUHSCTx has been minimal donor cell engraftment, well below therapeutic levels for most target diseases. Donor lymphocyte infusion (DLI) has been used in postnatal circumstances of mixed chimerism as targeted immunotherapy to achieve a graft-versus-hematopoietic effect and to increase levels of donor cell engraftment. In this report we demonstrate in the murine model that a combined approach of IUHSCTx followed by postnatal DLI can convert low-level, mixed hematopoietic chimerism to complete donor chimerism across full major histocompatibility complex barriers with minimal risk for graft-versus-host disease (GVHD). Time-dated embryonic day 14 (E14) to E15 Balb/c (H-2Kd, CD45.2) fetuses underwent intraperitoneal injection of 5 × 106T-cell–depleted B6 (H-2Kb, CD45.2) bone marrow cells. Chimeric recipients then received transplants at either 4 or 8 weeks of age with 1 of 3 doses (5, 15, or 30 × 106cells) of donor congenic splenocytes (B6-Ly5.2/Cr, H-2Kb, CD45.1). The response to DLI was dose dependent, with conversion to complete donor peripheral blood chimerism in 100% of animals that received high-dose (30 × 106 cells) DLI. Only 1 of 56 animals receiving this dose succumbed to GVHD. This study directly supports the potential therapeutic strategy of prenatal tolerance induction to facilitate nontoxic postnatal cellular therapy and organ transplantation, and it has broad implications for the potential treatment of prenatally diagnosed genetic disorders.

15 September 2002 in Blood
Verified
Journal Article
Closed access
PDF file
WPWilliam H. Peranteau
William H. Peranteau
SHSatoshi Hayashi
Satoshi Hayashi
MHMichael Hsieh
Michael Hsieh
ASAimen F. Shaaban
Aimen F. Shaaban
AFAlan W. Flake
Alan W. Flake
Clinical application of allogeneic bone marrow transplantation (BMT) has been limited by toxicity related to cytoreductive conditioning and immune response. In utero hematopoietic stem cell transplantation (IUHSCT) is a nonablative approach that achieves mixed chimerism and donor-specific tolerance but has been limited by minimal engraftment. We hypothesized that mixed chimerism achieved by IUHSCT could be enhanced after birth by nonmyeloablative total body irradiation (TBI) followed by same-donor BMT. To test this hypothesis, mixed chimerism was created by IUHSCT in a major histocompatibility complex-mismatched strain combination. After birth, chimeric animals received nonmyeloablative TBI followed by transplantation of donor congenic bone marrow cells. Our results show that: (1) low-level chimerism after IUHSCT can be enhanced to high-level chimerism by this strategy; (2) enhancement of chimerism is dependent on dose of TBI; (3) the mechanism of TBI enhancement is via a transient competitive advantage for nonirradiated hematopoietic stem cells; (4) engraftment observed in the tolerant, fully allogeneic IUHSC transplant recipient is equivalent to a congenic recipient; and (5) host-reactive donor lymphocytes are deleted with no evidence of graft-versus-host disease. This study supports the concept of prenatal tolerance induction to facilitate nonmyeloablative postnatal strategies for cellular therapy. If clinically applicable, such an approach could dramatically expand the application of IUHSCT.